First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.

Shengxiang RenXicheng WangBao-Hui HanYueyin PanJun ZhaoYufeng ChengSheng HuTianshu LiuYalun LiYing ChengJifeng FengShanyong YiShanzhi GuShegan GaoYongzhong LuoYing LiuCaigang LiuHuijie DuanShuni WangXinfeng YangJia FanCaicun Zhou

Published in: Journal for immunotherapy of cancer (2024)

NCT04346381.

Keyphrases

open label
small cell lung cancer
clinical trial
squamous cell carcinoma
phase ii
phase iii
phase ii study
advanced non small cell lung cancer
brain metastases
double blind
cross sectional
radiation therapy
rectal cancer